
EMA recommends approval of Etranacogen dezaparvovec
The At its meeting in December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a Recommendation for approval for Etranacogen dezaparvovec (Hemgenix, CSLBehring) given: Gene therapy should be used for severe and moderate haemophilia B (congenital factor IX deficiency) in adult patients without a history of […]